Interview with Jan De Backer, CEO, FluidDA
Dr De Backer looking into your background, we see that you have a background in aerospace engineering and applied biomedical computational fluid dynamics that is riddled with awards for your…
Address: Rue de Stallestraat 63/4, B-1180 Brussels,Belgium
Tel:
Web: http://www.octapharma.com/en.html
Our Group-wide mission is the safe and optimal use of human proteins.
Octapharma respects donated human plasma as a scarce and valuable resource. We meet our Mission through the use of cutting-edge, validated viral inactivation and state-of-the-art purification technologies, in order to achieve the highest production yields and manufacture medical products with the highest possible safety margins. We respect human plasma as a sparce resource for life saving therapies.
The Octapharma portfolio focuses on protein and other biopharmaceutical products derived from human plasma, in three therapeutic areas:
Haematology
Coagulation factors to treat bleeding disorders.
Intensive Care and Emergency Medicine
Plasma and blood proteins (such as albumin) used to stabilise blood circulation, restore coagulation function, and prevent shock, e.g., for heavy burns, injuries, and in surgery.
Immunotherapy
Immunoglobulins to treat immune disorders and prevent rhesus incompatibility in pregnancies.
Dr De Backer looking into your background, we see that you have a background in aerospace engineering and applied biomedical computational fluid dynamics that is riddled with awards for your…
Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud…
October marks the completion of your first full year as general manager of Cegedim’s Belgian affiliate. To what extent do you feel that the skills you’ve acquired in your career…
October marks the completion of your first full year as general manager of Cegedim’s Belgian affiliate. To what extent do you feel that the skills you’ve acquired in your career…
World Courier’s General Manager, Belgium After accumulationg an almost combined five decades of experience at World Courier, can you please tell our readers what it is that attracted the both…
Mr Noel Foucart, looking into your background, we see that you have accumulated almost 3 decades of experience at World Courier. Can you tell our readers what it is that…
Today, B&M differentiates itself by what it calls its ‘fluency’ in the way you think, work and behave which enables you to navigate the legal complexities across practices and boarders…
Mr Baudier, what inspired you when you joined the company back in 1978 and what are your main goals today? Prior to joining SMB Laboratories, I worked in a publishing…
Today, B&M differentiates itself by what it calls its ‘fluency’ in the way you think, work and behave which enables you to navigate the legal complexities across practices and boarders…
What was the motivation behind the establishment of BeCRO and why was it only established in 2010 given the strength of Belgium’s clinical trials industry? Philippe van der Hofstadt: Prior…
Historically, Belgium is widely recognized as a major regional hub for clinical development. How would you compare the current environment to 1999, when Archemin was first established, and how has…
An in-depth viewpoint on the current taxation situation for pharmaceutical companies operating in Belgium today, looking at incentive programs and relative positioning in Europe. Mr Eynatten, can you please…
See our Cookie Privacy Policy Here
